Brain medicine : from neurons to behavior and better healthJan 23, 2026

Adenosine's role in fast antidepressant effects: Understanding the coffee paradox

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

Adenosine signaling is presented as a shared metabolic pathway for several rapid-acting antidepressant therapies.

Evidence

A commentary or research summary describes Yue, Luo, and colleagues' genetically encoded sensor and mechanistic dissection work on ketamine, ECT, and acute intermittent hypoxia in mood-regulatory circuits.

Caveat

The abstract frames therapeutic and caffeine implications as unresolved questions rather than tested clinical outcomes in treatment-resistant depression.

Simplified

Yue, Luo, and colleagues discovered that adenosine signalling is the common underlying mechanism of rapid acting antidepressant therapies, unifying the effects of ketamine, ECT and acute intermittent hypoxia. They use genetically encoded sensors, along with extensive mechanistic dissection, to show that all three induce adenosine surges in mood-regulatory circuits via A1 and A2A receptor activation. The mechanism of action of ketamine primarily involves modulation of mitochondrial metabolism as opposed to NMDA receptor antagonism, thereby presenting the possibility for improvements in derivative products with better therapeutic indices. These outcomes offer a rational framework for gauging therapeutic benefit for depression and raise vexing questions about patterns of caffeine consumption in treatment resistant depression, specifically whether the chronic use has a protective effect or whether the acute use impedes treatment response.